Identification of high-quality HITs for tuberculosis (HIT-TB)

This project completed in May 2018.

Identification of High-Quality HITs for Tuberculosis (HIT-TB) was a collaborative project between the National Institute of Allergy and Infectious Diseases (NIAID) and academic institutions in the United Kingdom and South Africa. The project focused on combating tuberculosis, which infects approximately one-third of the world’s population and is becoming increasingly resistant to existing drugs. The goal of HIT-TB was to identify a series of well-characterized small molecules that had defined and tractable bacterial targets, which had the potential to be developed into better drugs to treat tuberculosis. The program sought to combine the power of the drug-discovery process high-throughput screening with chemically diverse small molecule libraries and target-based approaches to identify targets that have the potential for lead optimization.

Goals

  • To screen new libraries with novel sources of chemical diversity
  • Generation of sufficient SAR to establish quality of hit series
  • To identify vulnerable targets
  • To enrich screening libraries and results of screening using computational predictions
  • To identify targets of quality hit series

Partners

Public-Sector Partners:
National Institute of Allergy and Infectious Diseases (NIAID)

Private-Sector Partners:
Bill & Melinda Gates Foundation*

Academic Partners:
University of Cambridge
University of Cape Town
University of Dundee

*Provided financial or in-kind support for this program.

FNIH Contact

Susan Wiener, Senior Project Manager, swiener@fnih.org